Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
ANVISA issues CGMP to Concord Biotech’s Unit I
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Cipla completes transfer of Generics Business Undertaking
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Subscribe To Our Newsletter & Stay Updated
